Avaleht › Krooniline lümfotsütaarne leukeemia › Washington › Seattle
Krooniline lümfotsütaarne leukeemia kliinilised uuringud linnas Seattle, WA
20 uuringut haiguse Krooniline lümfotsütaarne leukeemia jaoks otsivad osalejaid linnas Seattle ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
VärbamineVaatlusuuringTerved vabatahtlikud oodatud
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- ja veel 1
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
VärbamineFaas 1/2
- Research Site, Seattle
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
VärbamineFaas 3
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- FHCC at Northwest Hospital, Seattle
- ja veel 1
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
VärbamineFaas 3
- Swedish Medical Center Swedish Cancer Institute First Hill Campus, Seattle
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
VärbamineFaas 1/2
- Fred Hutchinson Cancer Research Center, Seattle
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
VärbamineFaas 3
- Fred Hutchinson Cancer Research Center, Seattle
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
VärbamineFaas 1/2
- Fred Hutchinson Cancer Research Center, Seattle
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
VärbamineFaas 3
- Fred Hutchinson Cancer Research Center, Seattle
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
VärbamineFaas 3
- Fred Hutchinson Cancer Research Center, Seattle
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
VärbamineFaas 2
- Fred Hutchinson Cancer Center, Seattle
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
VärbamineFaas 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
VärbamineFaas 1
- Fred Hutch Cancer Center, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
VärbamineFaas 2Terved vabatahtlikud oodatud
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
VärbamineFaas 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
VärbamineFaas 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
VärbamineFaas 4
- Swedish Cancer Institute, Seattle
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
VärbamineFaas 4
- Swedish Cancer Institute, Seattle
Study of SGR-1505 in Mature B-Cell Neoplasms
VärbamineFaas 1
- Fred Hutchinson Cancer Center, Seattle
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
VärbamineFaas 2
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
VärbamineFaas 1
- Swedish Cancer Institute, Seattle
Krooniline lümfotsütaarne leukeemia uuringud teistes linnades
- Boston, MA31 uuringut
- Columbus, OH28 uuringut
- Durham, NC27 uuringut
- Washington, DC22 uuringut
- Rochester, MN19 uuringut
- New York City, NY18 uuringut
- Houston, TX17 uuringut
- Baldwin Park, CA16 uuringut
- Milwaukee, WI15 uuringut
- Cincinnati, OH14 uuringut
- Chicago, IL14 uuringut
- Nashville, TN13 uuringut
Muud uuringud linnas Seattle
- Mitteväikerakuline kopsuvähk53 uuringut
- Vähk (kõik liigid)49 uuringut
- Eesnäärmevähk42 uuringut
- Äge müeloidne leukeemia40 uuringut
- Rinnavähk39 uuringut
- Metastaatiline vähk39 uuringut
- Käär- ja pärasoolevähk34 uuringut
- Kopsuvähk33 uuringut
- Munasarjavähk30 uuringut
- Müeloom22 uuringut
- Müelodüsplastilised sündroomid21 uuringut
- Äge lümfoblastne leukeemia21 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.